Not a client yet? Request preview access to our pipeline database, forecast models and executive presentations.

Request preview access
Vaccine intelligence since 2007

Bringing life to vaccine strategy.

A boutique intelligence firm sitting between vaccine candidate and market. Founded in the UK in 2007, we blend disease insight, epidemiology, and commercial intelligence to drive vaccine portfolios forward.

Follow us:
~20
Years of vaccine focus
14
Vaccine therapeutic areas
8.3 bn
People worth protecting
∞
Questions worth asking
01 Portfolio

Mapping almost every new vaccine opportunity.

MarketVIEW is a targeted assessment of vaccine opportunity at the pathogen or disease level, combining robust epidemiology with forward-looking commercial analysis. Each product includes a detailed Excel-based value and volume forecast model, alongside an executive-ready presentation summarising key insights and strategic implications.

Elderly man - adult immunisation focus Pregnant woman - maternal immunisation focus Infant - paediatric vaccination focus Travellers with backpacks - travel vaccines Mother and child - endemic-region immunisation Adolescent girls - HPV and adolescent vaccines
Therapeutic focus 04

Endemic/diarrheal

02 News and latest analysis

Recent & forthcoming.

News archive
Endemic/diarrheal |Invasive non-typhoidal Salmonella

Invasive non-typhoidal Salmonella (iNTS) vaccines - forecast to 2047

iNTS is one of the most lethal bacterial infections of young children in sub-Saharan Africa, with an estimated 594,000 cases and 79,000 deaths worldwide, and there is still no licensed vaccine. Our assessment combines a registry-verified pipeline with a country-level demand and revenue forecast to 2047 across 49 sub-Saharan African countries. Register your interest ahead of publication.

Syndicated reportIn preparation
Endemic |Lyme borreliosis

Lyme borreliosis vaccines - forecast to 2040

Valneva and Pfizer's PF-07307405 narrowly missed its Phase 3 VALOR primary endpoint while showing 73-75% efficacy, and its EU application has now been validated by the EMA. The June 2020 edition was updated for travel in August 2026; the endemic-population update is in progress for Q4 2026, and the full syndicated refresh is subject to client buy-in.

Syndicated reportQ4 2026 update in progress
Travel |New & existing vaccines

New travel vaccines - segment forecast to 2040

The 2026 edition is complete and available to order. 13 marketed travel vaccines de-layered from their wider franchises across 13 origin markets - 169 anchored, confidence-graded country cells - plus 9 new product forecasts under three IATA-anchored scenarios. Includes the primary traveller survey.

Syndicated report2026 edition
Respiratory |Group A Streptococcus

Group A Streptococcus vaccines - forecast to 2045

No licensed GAS vaccine exists, yet severe disease still kills over half a million people a year - and GSK and Vaxcyte have both now entered the clinic. The 2026 edition comes as two model options: Western paediatric and older-adult indications, or developing-world rheumatic heart disease.

Syndicated report2026 edition
Respiratory |Flu/COVID-19 combination

Global seasonal influenza market + COMBOs to 2040

Sanofi versus CSL Seqirus - who's winning the race in global differentiated vaccines? What will be the impact of mRNA, now approved as a combination in the EU? Our new global analysis has the full picture.

Syndicated reportQ2 2026
Vaccine R&D pipeline |analysis

Strategic Vaccine & mRNA Pipeline Review

Analysis of 2,279+ Phase I–IV industry trials across 109 pathogens and 270 companies. Includes a dedicated mRNA landscape focus section covering Moderna, Pfizer, GSK, Sanofi and new entrants. June 2026 edition.

Syndicated reportQ2 2026
Free insight pages

Quick reads, live on the site now.

Lyme borreliosis · Phase 3 & EMA filing

Lyme vaccines: efficacy shown, Europe filed. Now the demand question.

LB6V delivered 73.2% efficacy in VALOR, presented at IDWeek 2026, with an EU application under EMA assessment. What it means for US and European demand - and the North American model now complete.

Read the insight →
Seasonal influenza · Adjuvanted

Adjuvanted flu: not just a 65+ vaccine anymore?

New CSL Seqirus US modeling makes the case for adjuvanted flu vaccines in adults 50-64, alongside the parallel Moderna and Sanofi regulatory moves into the same age band.

Read the insight →
Seasonal influenza · COVID-19

A single flu-COVID shot. Will older Americans take it?

US survey of 500+ adults 50+: 64% would accept a combination flu-COVID vaccine, but 60% didn't even know one was in development.

Read the insight →
Pipeline · New entrants

Eli Lilly enters the vaccine arena

A bolt-on M&A pipeline snapshot: Lilly's 3 acquired vaccine programmes benchmarked against 58 incumbent assets across 7 established manufacturers.

Read the insight →
EU5 · mRNA flu

Five EU5 markets. One mRNA flu league table.

Modelled mRNA flu penetration to 2035 across Germany, Spain, Italy, France and the UK - three scenarios, and the access triggers that could double revenue exposure.

Read the insight →
Travel & aviation · 2026

Continued growth. Emerging headwinds.

A record 5.2 billion air passengers forecast for 2026, but five structural IATA risks are moderating momentum - and reshaping travel vaccine demand.

Read the insight →
Staphylococcus aureus · Phase 3 topline

Olymvax says its Staph vaccine works. The field has not seen that before.

Chengdu Olymvax's Phase 3 topline for rFSAV hit 73.25% efficacy against a 60% target - a first for Staph vaccines in twenty years, and now under challenge from an anonymous report.

Read the insight →
03 Capability/Approach

Built around portfolio decisions, not slide formats.

Asset diligence

Mechanism, target product profile, comparator landscape, and probability-of-success framing for licensing or in-house pipeline decisions.

Indication mapping

Where adjacent vaccines, off-label use, and emerging epidemiology widen - or close - a commercial window.

Forecast review

Independent stress-test of internal forecasts: assumptions, sensitivity, payer behaviour, real-world uptake calibration.

Policy tracking

Continuous read of ACIP, JCVI, STIKO, HAS, NITAG signal - interpreted not just summarised.

Adult immunisation

Pneumococcal, RSV, zoster, influenza, COVID combinations - where adult uptake is being made or lost.

Maternal & paediatric

Schedule integration, programmatic constraints, equity dynamics across high- and low-income geographies.

Tender & access

UNICEF, PAHO, Gavi, EU joint procurement and national tender behaviour - and what it means for net price.

Travel vaccines

Expert insights on global travel immunization strategy, risk, and market analytics.

04 About

A vaccine intelligence identity, refreshed.

I believe vaccines are one of humanity's greatest achievements. Few innovations have saved as many lives, across every age group and every part of the world. That belief is what led me to found VacZine Analytics in 2007, to help our clients build the evidence, confidence, and momentum needed to bring the next generation of vaccines forward.

John Savopoulos, Group Director
Group Director
John Savopoulos
PhD  |  MBA

VacZine Analytics has been working alongside the vaccine industry since 2007 - long enough to remember when adult immunisation was a slide-deck afterthought, and long enough to know which questions are actually load-bearing. We are deliberately boutique: tight teams, deep files, no junior layer in front of the analyst.

Founded2007 |Refreshed identity 2026
Primary sector focusVaccines, Infectious Disease and immunoprophylaxis
New sector focusGene therapies - see our sister site www.genescope-intelligence.com
GeographiesGlobal |weighted US / EU / UK / G20
Engagement modelSyndicated |Bespoke
05 Contact

Request a briefing or report sample.

A short three-step request. We respond within two working days from a UK address. Lawful basis: consent (GDPR Art. 6(1)(a)).

Curious about cost first? See indicative MarketVIEW pricing.

What's on your mind?

Pick one or more. We'll tailor the materials we send.

Where do you sit?

One is fine - it just helps us pitch the framing right.

Where to send it.

Work email please - we don't send to free-mail accounts.

Please share your first name.
Please share your last name.
We need a valid work email (not free-mail).
Please share your organisation.
Thanks - we'll be in touch within two working days.

A copy has been routed to our analyst team. If you don't hear back, do drop us a line at [email protected].

Sorry - something went wrong sending that.

Please email us directly at [email protected] and we'll pick it up from there.

06 FAQ

Common questions, briefly answered.

How do you use AI in your research process?

We use AI tools selectively to support parts of our research and modelling work, helping our analysts work more efficiently. This includes our DemandENGINE™ forecasting technology, where analysts set and review every assumption. AI does not make decisions in our studies. Every analytical step, assumption and conclusion is decided by a human analyst, and anything produced with AI assistance is checked by an analyst before it informs a forecast or reaches a client. Our forecasts and recommendations remain the independent judgement of our analysts.

What does working with VacZine Analytics actually look like?

Usually one of two shapes: a syndicated report (single copy access) or a bespoke project with a defined deliverable and timeline. Both start with a 30-minute call so we can scope properly. All engagements run under our .

Do you publish public reports?

Selectively, but mainly through shorter white papers or expert pieces. Our syndicated catalogue reports which cover our focus therapeutic areas are licensable on a non-exclusive, non-transferable basis. Most other work is single-client and confidential. Ask for the catalogue and we'll send what's currently live.

How does VacZine Analytics report licensing work?

We license our syndicated reports on a non-exclusive, non-transferable basis. This is standard practice across market intelligence and data providers, and it means clients have broad rights to use the content internally for their own business purposes, but do not acquire ownership of the underlying intellectual property or the right to redistribute it. “Non-exclusive” allows us to license the same report to multiple organisations, keeping prices at a sustainable level, while “non-transferable” ensures that only the contracting client (and its authorised personnel) may access the materials, not external agencies, partners, or other third parties.

How is your work different from a big-three consultancy?

We're deliberately small and vaccine-only. There's no junior layer in front of the analyst, no rotating staffing, and no sector-tourist framing. We've been doing this since 2007 - the institutional memory is the product.

What about data and confidentiality?

Standard mutual NDA before any client material is shared. Our data infrastructure runs on UK-hosted services with role-based access. See the for what we collect on this site itself.

How do you handle policy / regulatory references?

Public-domain meetings, slide decks, and policy minutes - ACIP, JCVI, STIKO, HAS, EMA, FDA, WHO SAGE, MHRA - are read in primary form, not via news summaries. Trial registry IDs are checked against ClinicalTrials.gov and EU CTR. Sponsorship trademarks are used for identification only - see the credits line at the foot of the page.